Fig 1: Gating strategy for flow-cytometry based multiplex cytokine array, related to Fig. 3.Schema outlining the gating strategy used in the multiplex cytokine arrays and neutralizing antibody assay to define bead populations based on sideward-scatter (SSC), forward-scatter (FSC) and fluorescence signal in the red laser 670/14 channel. First row indicating gating schemas for cytokine panel 1 (741091, Biolegend, CA, USA), second row indicating gating for cytokine panel 2 (741142, Biolegend, CA, USA) and third row indicating gating for SARS-CoV-2 Neutralizing Antibody Assay (741127, Biolegend, CA, USA).
Fig 2: S1 neutralizing antibody concentrations after COVID-19 vaccination in ICI-treated patients, related to Fig. 4.Line-plots indicating neutralizing antibody concentrations of n = 40 individual patients after vaccination as assessed by an ACE2 S1 competitive immunoassay (research grade). Color code indicating vaccine type in the respective patients. Source data
Supplier Page from BioLegend for LEGENDplex™ SARS-CoV-2 Neut. Ab Assay (1-plex) w/ VbP